Menu Search
Equities

Aldeyra Therapeutics Inc

137:STU

Aldeyra Therapeutics Inc

Actions
  • Price (EUR)4.62
  • Today's Change0.148 / 3.31%
  • Shares traded0.00
  • 1 Year change+108.39%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Aldeyra Therapeutics Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 30.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 30.33m for operations while cash used for financing totalled 1.27m.
Cash flow per share-0.75
Price/Cash flow per share--
Book value per share1.43
Tangible book value per share1.43
More ▼

Balance sheet in USDView more

Aldeyra Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.50% of the market capitalization can be attributed to its 142.82m and debt could be paid in full if management chose.
Current ratio6.80
Quick ratio--
Total debt/total equity0.1796
Total debt/total capital0.1522
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.